- Home
- AIM vs BRN Comparison
AIM vs BRN Comparison
Compare AIM & BRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- BRN
- Stock Information
- Founded
- AIM 1966
- BRN 1956
- Country
- AIM United States
- BRN United States
- Employees
- AIM N/A
- BRN N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- BRN Oil & Gas Production
- Sector
- AIM Health Care
- BRN Energy
- Exchange
- AIM Nasdaq
- BRN Nasdaq
- Market Cap
- AIM 15.9M
- BRN 16.9M
- IPO Year
- AIM N/A
- BRN N/A
- Fundamental
- Price
- AIM $0.21
- BRN $1.65
- Analyst Decision
- AIM Strong Buy
- BRN
- Analyst Count
- AIM 2
- BRN 0
- Target Price
- AIM $2.75
- BRN N/A
- AVG Volume (30 Days)
- AIM 672.1K
- BRN 45.3K
- Earning Date
- AIM 11-15-2024
- BRN 02-10-2025
- Dividend Yield
- AIM N/A
- BRN N/A
- EPS Growth
- AIM N/A
- BRN N/A
- EPS
- AIM N/A
- BRN N/A
- Revenue
- AIM $190,000.00
- BRN $21,724,000.00
- Revenue This Year
- AIM N/A
- BRN N/A
- Revenue Next Year
- AIM $1,693.10
- BRN N/A
- P/E Ratio
- AIM N/A
- BRN N/A
- Revenue Growth
- AIM N/A
- BRN N/A
- 52 Week Low
- AIM $0.16
- BRN $1.31
- 52 Week High
- AIM $0.62
- BRN $3.20
- Technical
- Relative Strength Index (RSI)
- AIM 50.86
- BRN 53.09
- Support Level
- AIM $0.19
- BRN $1.53
- Resistance Level
- AIM $0.23
- BRN $1.69
- Average True Range (ATR)
- AIM 0.02
- BRN 0.12
- MACD
- AIM -0.00
- BRN 0.02
- Stochastic Oscillator
- AIM 48.29
- BRN 79.07
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.